AU2005286965B2 - Quinolone analogs as cell proliferation inhibitors - Google Patents

Quinolone analogs as cell proliferation inhibitors Download PDF

Info

Publication number
AU2005286965B2
AU2005286965B2 AU2005286965A AU2005286965A AU2005286965B2 AU 2005286965 B2 AU2005286965 B2 AU 2005286965B2 AU 2005286965 A AU2005286965 A AU 2005286965A AU 2005286965 A AU2005286965 A AU 2005286965A AU 2005286965 B2 AU2005286965 B2 AU 2005286965B2
Authority
AU
Australia
Prior art keywords
compound
ring
optionally substituted
mmol
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005286965A
Other languages
English (en)
Other versions
AU2005286965A1 (en
Inventor
Peter Chua
Michael Jung
Johnny Y. Nagasawa
Fabrice Pierre
Collin Regan
Michael Schwaebe
Jeffrey P. Whitten
George Petros Yiannikouros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senhwa Biosciences Inc
Original Assignee
Senhwa Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/149,007 external-priority patent/US7652134B2/en
Application filed by Senhwa Biosciences Inc filed Critical Senhwa Biosciences Inc
Publication of AU2005286965A1 publication Critical patent/AU2005286965A1/en
Application granted granted Critical
Publication of AU2005286965B2 publication Critical patent/AU2005286965B2/en
Assigned to SENHWA BIOSCIENCES, INC. reassignment SENHWA BIOSCIENCES, INC. Request for Assignment Assignors: CYLENE PHARMACEUTICALS, INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2005286965A 2004-09-17 2005-09-16 Quinolone analogs as cell proliferation inhibitors Expired AU2005286965B2 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US61103004P 2004-09-17 2004-09-17
US60/611,030 2004-09-17
US63860304P 2004-12-22 2004-12-22
US60/638,603 2004-12-22
US68898605P 2005-06-09 2005-06-09
US68879605P 2005-06-09 2005-06-09
US11/149,007 2005-06-09
US60/688,986 2005-06-09
US11/149,007 US7652134B2 (en) 2004-09-17 2005-06-09 Methods for converting quinolone esters into quinolone amides
US60/688,796 2005-06-09
PCT/US2005/033323 WO2006034113A2 (en) 2004-09-17 2005-09-16 Quinolone analogs as cell proliferation inhibitors

Publications (2)

Publication Number Publication Date
AU2005286965A1 AU2005286965A1 (en) 2006-03-30
AU2005286965B2 true AU2005286965B2 (en) 2009-10-22

Family

ID=35735203

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005286965A Expired AU2005286965B2 (en) 2004-09-17 2005-09-16 Quinolone analogs as cell proliferation inhibitors

Country Status (11)

Country Link
US (1) US7816406B2 (enExample)
EP (1) EP1802306A2 (enExample)
JP (1) JP2008513485A (enExample)
KR (1) KR100989029B1 (enExample)
AU (1) AU2005286965B2 (enExample)
BR (1) BRPI0515319A (enExample)
CA (1) CA2580749C (enExample)
IL (1) IL181857A0 (enExample)
MX (1) MX2007003282A (enExample)
NZ (1) NZ553746A (enExample)
WO (1) WO2006034113A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1928887B1 (en) 2005-08-05 2014-12-17 Senhwa Biosciences, Inc. Methods of preparing quinolone analogs
US20110112086A1 (en) * 2006-06-08 2011-05-12 Cylene Pharmaceuticals, Inc. Pyridinone analogs
WO2007146831A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
DK2061765T3 (en) 2006-09-01 2015-01-26 Senhwa Biosciences Inc Serine-threonine protein kinase AND PARP-MODULATOR
WO2009002870A1 (en) * 2007-06-22 2008-12-31 Cylene Pharmaceuticals, Inc. Methods for treating aberrant cell proliferation disorders
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
CA2698463A1 (en) * 2007-08-31 2009-08-06 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
NZ583878A (en) 2007-09-14 2012-10-26 Vertex Pharma Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
KR101601332B1 (ko) * 2007-10-05 2016-03-08 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이와 관련된 방법
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
RU2435758C1 (ru) * 2010-07-19 2011-12-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения этилового эфира 3-оксо-3-(2,6-дихлорпиридин-3-ил) пропановой кислоты
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
BR112016026150B1 (pt) 2014-05-09 2019-11-05 Pimera, Inc. compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer
WO2016137471A1 (en) * 2015-02-26 2016-09-01 Nantpharma, Llc Method for enhanced heparin quality
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
ES2959536T3 (es) * 2015-12-14 2024-02-26 Senhwa Biosciences Inc Formas cristalinas de análogos de quinolona y sus sales
JP2020512975A (ja) 2017-03-28 2020-04-30 ピメラ，インク． Ｐｏｌ１阻害剤の新規な結晶形態
EP3752149A4 (en) 2018-02-15 2022-03-02 Senhwa Biosciences, Inc. QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
IL328679A (en) * 2023-11-28 2026-07-01 Genome Therapeutics Ltd Tetracyclic compounds for use in antibody-drug conjugates for cancer treatment
WO2025242908A2 (en) * 2024-05-24 2025-11-27 Genome Therapeutics Ltd Novel compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
DE3267485D1 (en) 1981-02-18 1986-01-02 Nippon Shinyaku Co Ltd Substituted carboxylic acid derivatives
ZA852802B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzoxazolo-quinoline antibacterial compounds
ZA852769B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzothiazolo-quinoline antibacterial compounds
US4528285A (en) 1984-04-26 1985-07-09 Abbott Laboratories Methylenedioxy quino-benzothiazine derivatives
WO1989012055A1 (fr) 1988-06-08 1989-12-14 Kyorin Pharmaceutical Co., Ltd. Agent antitumoral
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
IE912902A1 (en) 1990-08-24 1992-02-26 Abbott Lab Quinbenzoxazine, quinobenzothiazine, and pyrido-acridine¹antineoplastic agents
JPH04117388A (ja) * 1990-09-07 1992-04-17 Hokuriku Seiyaku Co Ltd チアゾロキノリン―４―カルボン酸誘導体
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
ATE304539T1 (de) 2000-12-14 2005-09-15 Procter & Gamble Antimikrobielle chinolone
US6821969B2 (en) * 2001-02-13 2004-11-23 Pharmacia & Upjohn Company Thioxazinoquinolones as antiviral agents
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
JP2006522827A (ja) 2003-04-07 2006-10-05 サイリーン ファーマシューティカルズ インコーポレーティッド 置換キノベンゾオキサジン類似体
ATE451924T1 (de) 2004-03-15 2010-01-15 Sunesis Pharmaceuticals Inc Sns-595 und anwendungsverfahren

Also Published As

Publication number Publication date
KR20070085264A (ko) 2007-08-27
KR100989029B1 (ko) 2010-10-25
US20060074089A1 (en) 2006-04-06
AU2005286965A1 (en) 2006-03-30
CA2580749C (en) 2014-01-28
MX2007003282A (es) 2007-10-16
JP2008513485A (ja) 2008-05-01
EP1802306A2 (en) 2007-07-04
WO2006034113A2 (en) 2006-03-30
IL181857A0 (en) 2007-07-04
US7816406B2 (en) 2010-10-19
BRPI0515319A (pt) 2008-07-22
CA2580749A1 (en) 2006-03-30
WO2006034113A3 (en) 2006-08-24
NZ553746A (en) 2010-06-25

Similar Documents

Publication Publication Date Title
US7816406B2 (en) Quinolone analogs
US20090215761A1 (en) Quinobenzoxazine analogs and methods of using thereof
AU2008308485B2 (en) Quinolone analogs and methods related thereto
US20110065687A1 (en) Hydrazide compounds and uses thereof
AU2004229489B2 (en) Substituted quinobenzoxazine analogs
US20100063046A1 (en) Tetracyclic imidazole analogs
US7507727B2 (en) Substituted quinobenzoxazine analogs and methods of using thereof
US7163948B2 (en) Heterocyclic substituted 1,4-dihydri-4ox9-1,8-naphthyridine analogs
US7354916B2 (en) Substituted quinobenzoxazine analogs
RU2349586C2 (ru) Аналоги хинолона
ZA200508093B (en) Substituted quinobenzoxazine analogs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SENHWA BIOSCIENCES, INC.

Free format text: FORMER OWNER WAS: CYLENE PHARMACEUTICALS, INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired